Treatment of bone-associated cancers
AssigneePoniard Pharmaceuticals, Inc.
InventorsAlan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
Claims20
A therapeutic method for treating a bone-associated cancer comprising:
- (a) parenterally administering a dose of 153Sm-EDTMP to said patient in an aqueous vehicle comprising an effective antiradiolytic amount of a pharmaceutically acceptable radioprotectant;
- and
- (c) administering to said patient an effective amount of chemotherapeutic agent in conjunction with 153Sm-EDTMP wherein the patient is not subjected to total body irradiation or stem cell transplantation in conjunction with the therapeutic method.
A therapeutic method for treating a bone-associated cancer comprising:
- (a) parenterally administering a dose of 153Sm-EDTMP to said patient in an aqueous vehicle;
- and
- (c) administering to said patient an effective amount of a bisphosphonate in conjunction with said 153Sm-EDTMP wherein the patient is not subjected to total body irradiation or stem cell transplantation in conjunction with the therapeutic method.
Dependencies are inferred from the claim text.